Panbela Announces Pricing of Approximately $6 Million Public Offering

On September 30, 2022 Panbela Therapeutics, Inc. (Nasdaq: PBLA), ("Panbela" or the "Company"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, reported the pricing of a public offering of (i) 20,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 30,150,000 shares of its common stock (the "Public Warrants") at a purchase price of $0.30 per share and associated Public Warrant (Press release, Panbela Therapeutics, SEP 30, 2022, View Source [SID1234621578]). The Public Warrants will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about October 4, 2022, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roth Capital Partners, LLC is acting as lead placement agent, Craig-Hallum Capital Group LLC and Maxim Group LLC are each acting as co-placement agent of the offering.

Gross proceeds, before deducting placement agent fees and commissions and offering expenses are expected to be approximately $6 million. The Company intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates ivospemin (SBP-101) and eflornithine (CPP-1X), working capital, business development and other general corporate purposes, which may include repayment of debt.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-267000), as amended, that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on September 29, 2022. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained, when available, at the SEC’s website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at [email protected].

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About our Pipeline

The pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer. The combined development programs have a steady cadence of catalysts with programs ranging from pre-clinical to registration studies.

SBP-101 Ivospemin

Ivospemin is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. It has shown signals of tumor growth inhibition in clinical studies of metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 14.6 months and an objective response rate (ORR) of 48%, both exceeding what is typical for the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, ivospemin has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the previous Panbela-sponsored clinical trials provide support for continued evaluation of ivospemin in the ASPIRE trial. For more information, please visit View Source .

Flynpovi

Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increase polyamine export and catabolism. In a Phase 3 clinical trial in patients with sporadic large bowel polyps, the combination prevented > 90% subsequent pre-cancerous sporadic adenomas versus placebo. Focusing on FAP patients with lower gastrointestinal tract anatomy in the recent Phase 3 trial comparing Flynpovi to single agent eflornithine and single agent sulindac, FAP patients with lower GI anatomy (patients with an intact colon, retained rectum or surgical pouch), Flynpovi showed statistically significant benefit compared to both single agents (p≤0.02) in delaying surgical events in the lower GI for up to four years. The safety profile for Flynpovi did not significantly differ from the single agents and supports the continued evaluation of Flynpovi for FAP.

CPP-1X

CPP-1X (eflornithine) is being developed as a single agent tablet or high dose power sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes. Preclinical studies as well as Phase 1 or Phase 2 investigator-initiated trials suggest that CPP-1X treatment may be well-tolerated and has potential activity.

INTERIM RESULTS for the six months ended 30 June 2022

On September 30, 2022 ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, reported its interim results for the six months ended 30 June 2022 (the "Period") (Press release, ImmuPharma, SEP 30, 2022, View Source [SID1234621577]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Highlights (including post Period review)

Financials

Financial performance in line with expectations over the Period
Loss for the Period of £1.7m (30 June 2021: £3.7m)
Research and development expenses of £1.0m (30 June 2021: £1.1m)
Administrative expenses of £0.6m (30 June 2021: £0.9m)
Share based expense of £0.1m (30 June 2021: £0.3m)
Cash balance of £0.2m as at 30 June 2022 (31 December 2021: £1.6m)
Derivative financial asset of £0.6m as at 30 June 2022 (31 December 2021: £0.9m)
Incanthera financial asset of £0.6m (£1.2m at 31 December 2021) and warrants financial asset of £Nil (£0.2m at 31 December 2021)
Basic and diluted loss per share of 0.58p (30 June 2021: 1.46p)
Reorganisation of share capital structure in June 2022
Successful fundraising in August 2022 raising £2.04m (gross), including Lanstead subscription, placement and broker option
Total proceeds of £0.3m from exercise of share options by L1 Capital in August 2022 and in September 2022
‘Autoimmunity’: Lupuzor ("P140")

P140 Pharmokinetic ("PK") study successfully completed with key endpoints met. P140 was safe and well tolerated across all doses and in all subjects
FDA Type C written response received on 14 September 2022: The FDA response was detailed and included significant guidance on next steps for the clinical programme. This included advice on the dosing regime and on study protocol that can be amended to improve the regulatory outcome
The Company is currently reviewing the written response with Avion and will make a further notification in due course
An adaptive Phase 2/3 clinical study protocol of P140 in CIDP is being finalised for IND submission. Commercial partnering discussions ongoing
‘Anti-Infection’

BioAMB – further pre-clinical studies are in preparation
BioCin – further pre-clinical studies are in preparation
New website launched: www.immupharma.co.uk

Commenting on the statement and outlook, Tim McCarthy, CEO and Chairman, said:

"The last six months have been pivotal for the Company, positively concluding the PK study of Lupuzor ("P140"). Post the recent written response from the FDA, in respect to the Lupuzor Phase 3 protocol, we continue to have positive discussions with our partner, Avion, on the way forward.

The new fundraising, supported by existing and new shareholders, allows us to further invest in the other parts of our product portfolio, whilst being focused on preserving cash where required.

Moving forward, we remain focused on creating a robust and successful Company that, with a diversity of assets, will build future value for our shareholders.

The Board would like to take this opportunity to thank its shareholders for their continued patience and support, as well as its staff, corporate and scientific advisers and our partners including, CNRS and Avion".

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Scandion Oncology announce topline results from part 2 of the CORIST phase II trial

On September 30, 2022 Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, reported the topline results from the second part of the ongoing CORIST phase II trial studying Scandion’s lead compound SCO-101 as a combination treatment with FOLFIRI chemotherapy in patients with metastatic colorectal cancer (mCRC) (Press release, Scandion Oncology, SEP 30, 2022, View Source,c3639117 [SID1234621576]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The results confirm the safety and tolerability of SCO-101 in this indication and combination. Further, tumor reduction has been observed in some patients, however below the +30% threshold defined as the trial’s primary endpoint. Also, evidence of prolonged progression free survival and stable disease (secondary endpoints) were observed in this hard-to-treat refractory patient population.

Importantly, the data is obtained from the 25 patients enrolled in CORIST part 2, more of whom have only been evaluated after eight weeks of treatment. Patients are still participating in the study, which means that the topline results are not final and could change with longer treatment.

"While we do not achieve a clinical proof of concept for efficacy through these topline results, we are encouraged by the signals observed in the trial, confirming the rationale for combining SCO-101 and FOLFIRI in this indication. We look forward to continuing the development by progressing the CORIST trial further as planned," says Johnny Stilou, acting CEO of Scandion.

Scandion will continue the CORIST trial enrolling up to 36 patients to be treated according to an optimized dosing schedule as part 3 of the trial. Based on an improved understanding of the pharmacokinetics of SCO-101 in combination with FOLFIRI, increased doses of SCO-101 and chemotherapy will be explored aiming to exploit the full potential of SCO-101 in this indication and combination. The first patient is expected to be enrolled in CORIST part 3 shortly.

Depending on the dose escalation results, CORIST part 3 may be completed by Q3 2023, with an update on the timeline expected in Q1 2023. Scandion then expects to conduct part 4 of the trial, which will conclude the combined CORIST trial.

Webcast and conference call on October 4 at 10:00 am CET

On October 4 at 10:00 am, Scandion Oncology’s executive management will host a webcast and conference call about the topline results from the second part of CORIST.

The event can be accessed via www.scandiononcology.com or through dial in on below numbers:

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on September 30, 2022, at 10.30 CET.

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies

On September 30, 2022 Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, reported the launch of Oncology FACETS: an educational platform for healthcare providers that will address clinically impactful topics in gynecologic oncology (Press release, Mersana Therapeutics, SEP 30, 2022, View Source [SID1234621575]). Oncology FACETS is driven by a Steering Committee of experts in gynecologic oncology and offers content developed in collaboration with Mersana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our goal is to create a destination where oncologists can find up-to-date, peer-reviewed educational content on emerging topics about ovarian, endometrial, cervical, and other gynecological cancers," said Dr. Thomas J. Herzog of the University of Cincinnati, who is serving as Steering Committee Chair. "We believe Oncology FACETS will provide a valuable resource for physicians seeking to keep pace with this field’s rapidly evolving science and data."

Each Oncology FACETS educational module is led by a Steering Committee member. The first module is "Current and Emerging Biomarkers in Gynecologic Cancer," led by Dr. Rebecca C. Arend, a leading gynecologic oncologist at the University of Alabama at Birmingham. The module is now available for download at OncologyFACETS.com.

Dr. Arend noted, "Precision medicine is now at the forefront of the oncology field. Biomarkers are central to this movement, and their use in gynecologic malignancies promises to shape the treatment paradigm in the near future. This module is intended to both educate and facilitate peer-to-peer dialogue about this important topic."

Oncology FACETS will release new modules on a regular basis. The next module, planned to be released in December 2022, will focus on antibody-drug conjugates (ADCs) in gynecologic malignancies.

"We are proud to collaborate with this esteemed group of gynecologic oncologists to advance knowledge and patient care," said Anna Protopapas, President and Chief Executive Officer of Mersana. "Oncology FACETS is a natural extension of our commitment to driving innovation aimed at improving outcomes for women with gynecologic cancers."

About Oncology FACETS
Oncology FACETS is the outcome of a collaboration between the Oncology FACETS Steering Committee and Mersana Therapeutics, Inc. Oncology FACETS disseminates educational resources to advance the learning of practicing healthcare professionals; it is not intended as medical advice and includes information on both approved medications and investigational agents not yet approved for use in any country. The committee of experts in gynecologic oncology was assembled to provide guidance and approval of the material contained within this website. Mersana provides financial, administrative, and writing support to the Steering Committee in developing these resources. Oncology FACETS is not an accredited provider of continuing medical education.

The Oncology FACETS Steering Committee members include Thomas J. Herzog, MD, University of Cincinnati (serving as Chair); Rebecca C. Arend, MD, MSPH, University of Alabama at Birmingham; John L. Hays, MD, PhD, Ohio State University; Bhavan Pothuri, MD, PhD, New York University; Leslie M. Randall, MD, MAS, Virginia Commonwealth University; and Ritu Salani, MD, MBA, University of California, Los Angeles. Committee members provide guidance on the development of all educational material. They represent diverse geographic regions across the United States.

Each educational module is led by a Steering Committee member. The first educational module is available for download at OncologyFACETS.com. A second module is in progress and will be released in December 2022. Associated content and updates can be followed @OncologyFACETS on Twitter.

Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

On September 30, 2022 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported financial results for the first six months of 2022 and provided an update on clinical and corporate progress (Press release, Vivoryon Therapeutics, SEP 30, 2022, View Source [SID1234621574]). The report is available on the Company’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first half of 2022 was marked by decisive progress in the development of our lead candidate varoglutamstat in AD, which cumulated in several data presentations at the prestigious AAIC 2022 in San Diego in July and August," said Dr. Ulrich Dauer, CEO of Vivoryon. "Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study. At the same time, adding to the preclinical data package by characterizing the additive effect of varoglutamstat in combination with anti-Abeta antibodies, we continue to explore the full potential for its application in a variety of therapeutic settings. These data, which have sparked excitement within the medical community and beyond, substantiate our commitment to making a difference to all those affected by Alzheimer’s disease. Having secured a significant private placement will enable us to continue to follow our carefully crafted development strategy. We warmly welcome our new investor KKR Dawn Aggregator L.P. and are very grateful to them and to our longstanding investor Claus Christiansen for their support through the upcoming clinical milestones."

Portfolio Highlights (H1 2022 and post-period)

VIVIAD

VIVIAD (NCT04498650) is a state-of-the-art Phase 2b study conducted in Europe and designed to evaluate the safety, tolerability and efficacy of varoglutamstat in 250 subjects with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD).
On June 23, 2022, Vivoryon announced that it has completed the parallel group, dose-finding part of its VIVIAD study and that the independent Data Safety Monitoring Board (DSMB) has selected the highest dose investigated, 600 mg twice daily (BID), as the final dose to be administered in the second part of the study. The DSMB decision is based on safety data from 181 patients, 90 of which had completed the week 24 treatment visit at the May 17 cut-off date. All subjects randomized to the treatment arm will be treated at the selected dose of 600 mg BID moving forward and will continue treatment for up to 48-96 weeks dependent on study entry date.
Vivoryon presented detailed safety data from the VIVIAD study at the Alzheimer’s Association International Conference (AAIC) in San Diego (July 31 to August 4, 2022). The safety data showed that varoglutamstat was well tolerated with only 14% of overall reported adverse events (AEs) considered to be potentially related to study treatment. All of the AEs were gastrointestinal, general, or related to the nervous system or skin. Only four patients (2.2%) experienced serious AEs (SAEs) and only two patients (1.1%) discontinued the study. Both the total number of SAEs and the discontinuation rate were considerably lower than the respective numbers at the 800 mg BID varoglutamstat dose in Vivoryon’s completed Phase 2a SAPHIR study (NCT02389413; 15% SAEs, 33% discontinuation), while retaining a similar level of target inhibition.
VIVIAD is actively enrolling patients at 22 study centers in five European countries and will continue to evaluate its primary and secondary outcome measures, which include multiple cognitive, safety and biomarker endpoints. Vivoryon remains on track for final data readout for the study in the second half of 2023.
VIVA-MIND

VIVA-MIND (NCT03919162) is a combined Phase 2a/b study for varoglutamstat conducted in the U.S. which seeks to enroll 180 patients with early AD into the Phase 2a adaptive dose finding part. If predefined criteria are fulfilled, the trial will pass a stage-gate into the Phase 2b part, enrolling an additional 234 patients treated at the selected dose for at least 72 weeks. Thus, taken together a total of 414 patients will be treated on stable doses of varoglutamstat for 18 months in the course of the study. The primary endpoint for this study is CDR-SB (clinical dementia rating scale – sum of boxes), an established approvable endpoint measuring a combination of cognitive abilities and activities of daily living. The study is coordinated by the Alzheimer’s Disease Cooperative Study (ADCS), and supported by a USD15 million grant from the National Institute on Aging (NIA award number R01AG061146).
VIVA-MIND is actively enrolling patients, with currently 14 sites open and on track for an interim futility analysis planned for the first half of 2023.
Preclinical Programs

Also at AAIC 2022, Vivoryon presented preclinical data on the Company’s N3pE amyloid-targeting molecules. The results underscore the unique potential of Vivoryon’s N3pE amyloid-targeting therapeutic strategy in both mono- and combination therapy settings in AD. The data show, that a combination treatment of aducanumab and varoglutamstat achieves additive effect on Abeta pathology, indicating feasibility of dose reduction to improve safety of Abeta antibody-based AD treatments. This demonstrates the potential benefit of a combination therapy designed to simultaneously make use of two different and independent molecular N3pE-related mode of actions – small molecule based QPCT/L inhibition and anti-N3pE-immunotherapy. Additional data from murine analog of PBD-C06 highlight the differentiated safety profile vs. other anti-Abeta antibodies at N3pE amyloid-lowering concentrations.
Partnered Programs

On February 28, 2022, Vivoryon and its partner Simcere announced that China’s Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has approved the Clinical Trial Application for varoglutamstat for the development in Greater China by Simcere. Simcere has communicated that the company is currently preparing for initiation of clinical studies in China.
Corporate Development Highlights (H1 2022 and post-period)

On September 30, 2022, the Company entered into a private placement of 2,054,796 registered shares at an offering price of EUR 7.30 per share. The new shares from the capital increase represent 9.3% of Vivoryon’s existing share capital and will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights. Consequently, the Company’s issued share capital will increase to EUR 24,105,278.00 on completion of the private placement. In addition, the investors will have the option to purchase, in aggregate, up to another 2,054,796 registered shares at a price of EUR 7.30 during a period ending twelve months after the date of the approval of a EU Recovery prospectus (in accordance with Section 14a Prospectus Regulation) or three months after the achievement date of a defined clinical milestone, whichever is later. The gross proceeds of the private placement amount to EUR 15.0 million, and up to an additional EUR 15.0 million will be raised if the option to purchase the additional shares is exercised in full. Vivoryon intends to use the net proceeds from the offering to support the ongoing clinical development of its lead candidate varoglutamstat, currently in Phase 2 in Europe and the United States for the treatment of patients with Alzheimer’s disease, as well as for general corporate purposes. The private placement was supported by Vivoryon’s longstanding investor Claus Christiansen and KKR Dawn Aggregator L.P. ("Dawn Biopharma"), a platform controlled by affiliates of Kohlberg Kravis Roberts & Co. L.P. ("KKR"), a leading global investment firm, as new investor to the Company. Completion of the private placement is expected to occur on October 6, 2022.
In an in-person and webcasted breakfast and networking event at AAIC 2022, held on August 2, 2022, Vivoryon met with researchers, clinicians and the investment community to discuss the future of AD treatments and provided updates on its VIVA-MIND and VIVIAD studies for varoglutamstat. The event also featured spotlight presentations by Prof. Howard Feldman, MD, Professor of Neurosciences and Director of the ADCS at UC San Diego and VIVA-MIND study director, Cynthia Lemere, PhD, Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston and Dr. Frank Weber, CMO of Vivoryon.
On June 22, 2022, Vivoryon held its Annual General Meeting where all voting items were approved with a large majority. Voting items included the re-appointment of Charlotte Lohmann, Dr. Erich Platzer, Dr. Dinnies von der Osten and Dr. Jörg Neermann as members of the Company’s Non-Executive Board, as well as the appointment of Dr. Claudia Riedl and Samir Shah, MD, to its Non-Executive Board of Directors.
On April 1, 2022 Vivoryon announced the successful completion of a private placement, raising gross proceeds of EUR 21 million, with net proceeds from the offering intended to be used to support the ongoing clinical development of varoglutamstat, as well as for general corporate purposes. The capital raise was supported by a number of high-quality institutional investors from Europe and the U.S. as well as members of Vivoryon’s Executive and Non-Executive Boards.
Financial Results for the First Half Year 2022

The Company generated no license revenues or smaller revenue in half year 2022 or 2021.

Research and development expenses increased in 2022 by EUR 1.6 million compared to the six months ended June 30, 2021. This increase is primarily attributable to EUR 1.7 million higher expenses related to our clinical trial VIVIAD, which has advanced significantly compared to the six months ended June 30, 2021.

General and administrative expenses for the six months ended June 30, 2022 are about the same level as for the six months ended June 30, 2021. Higher expenses for share based payments with EUR 0.3 million were compensated by EUR 0.3 million lower expenses for legal and consulting services.

Net loss for the six months ended June 30, 2022 was EUR 12.6 million, compared to EUR 11.7 million for the six months ended June 30, 2021. The Company held EUR 24.4 million in cash and cash equivalents as of June 30, 2022, compared to EUR 14.7 million as of December 31, 2021.

Cash flows provided from financing activities were EUR 19.6 million for the six months ended June 30, 2022 compared to cash used in financing activities of EUR 0.5 million in the six months ended June 30, 2021. The change mainly relates to a private placement on April 1, 2022 by way of accelerated book building, placing 2,000,000 registered shares at an offering price of EUR 10.50 per share. The Company’s issued share capital has increased to EUR 22,050,482. The gross proceeds of the offering amounted to EUR 21.0 million.

Financial Guidance

Including the proceeds from the private placement entered into on September 30, 2022, according to current planning and estimates, Vivoryon expects that its existing cash and cash equivalents will be sufficient to fund its research and development expenses as well the general and administrative expenses and cash flows from investing and financing activities at least through December 2023. This does not include the exercise of the option to acquire up to an additional 2.054.796 shares for a period ending the later of twelve months after the date of the approval of a EU Recovery prospectus (in accordance with Section 14a Prospectus Regulation) or the achievement date of a defined clinical milestone.

Vivoryon Therapeutics N.V. Financial Statements

Condensed Statements of Profit or Loss and Other Comprehensive Income for the six months ended June 30, 2022 and 2021

The accompanying notes are an integral part of these condensed interim financial statements.

The accompanying notes are an integral part of these condensed interim financial statements.

The accompanying notes are an integral part of these condensed interim financial statements.

Half Year Financial Report 2022

The condensed interim financial statements of Vivoryon have been prepared in accordance with IAS 34 Interim Financial Reporting and International Financial Reporting Standards (IFRS) of the International Accounting Standards Board, as adopted by the European Union (EU-IFRS). The half-year financial statements were not audited or reviewed. The reports are available on the Company’s website www.vivoryon.com.

Conference Call and Webcast

Vivoryon will host a conference call and webcast today, September 30, 2022, at 3:00 pm CEST (9:00 am EDT). A Q&A session will follow the presentation of the full year results.

Please dial in ten minutes prior to commencement.

A live webcast and slides will be made available at: www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/

Approximately one day after the call, a slide-synchronized audio replay of the conference will be available on: www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/